Regenexx

Regenexx was the first to use stem cells from bone marrow concentrate to treat orthopedic injuries, and we've published roughly half of all worldwide research in their application. Through the Regenexx Corporate Program more than 2.000 employer groups have added the Regenexx benefit onto their self-funded health plan. We use our advanced regenerative technologies to help self-funded employers save up to 70% of their orthopedic healthcare costs by providing a non-surgical, lower cost alternative to roughly 70% of elective orthopedic surgeries. Most importantly, the Regenexx benefit gives employees a non-surgical option in care to help reduce pain and improve function that they wouldn’t have covered otherwise. Regenexxx licenses our injectates and processes to a highly skilled network of physicians. Regenexx lab processing routinely achieves 20x concentration of stem cell-containing bone marrow — far above what non-Regenexx processing can achieve. Learn more about the Regenexx approach and how we help employers take control of their health care spend. Visit www.Regenexx.com and www.Regenexxcorporate.com for more information.